The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of biologic agents in patients with metastatic colorectal cancer by race/ethnicity.
 
Seda Serra Tolu
No Relationships to Disclose
 
Adel Chergui
No Relationships to Disclose
 
Devika Rao
Stock and Other Ownership Interests - Baxter (I); Baxter (I); Baxter (I); Baxter (I)
 
Meghan Kaumaya
No Relationships to Disclose
 
Ana Acuna-Villaorduna
No Relationships to Disclose
 
Andreas Kaubisch
Other Relationship - Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
 
Jennifer W. Chuy
No Relationships to Disclose
 
Lakshmi Rajdev
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb, Boston Biomedical (Inst); Bristol Myers Squibb, Boston Biomedical (Inst); Bristol Myers Squibb, Boston Biomedical (Inst); Bristol Myers Squibb, Boston Biomedical (Inst)
 
Tarek N. Elrafei
No Relationships to Disclose
 
Sanjay Goel
Research Funding - BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Oncolytics (Inst); Oncolytics (Inst); Oncolytics (Inst); Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364; I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364; I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364; I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364